Intuitive Surgical (NASDAQ:ISRG) PT Raised to $555.00 at Royal Bank of Canada

Intuitive Surgical (NASDAQ:ISRG) had its price objective hoisted by stock analysts at Royal Bank of Canada from $525.00 to $555.00 in a note issued to investors on Friday, Marketbeat.com reports. The brokerage presently has an “outperform” rating on the medical equipment provider’s stock. Royal Bank of Canada’s target price would indicate a potential upside of 6.50% from the stock’s previous close.

Several other brokerages have also weighed in on ISRG. Barclays upped their target price on shares of Intuitive Surgical from $430.00 to $490.00 and gave the stock an “overweight” rating in a research report on Thursday, July 18th. Mizuho lifted their price objective on Intuitive Surgical from $440.00 to $500.00 in a report on Thursday. Morgan Stanley boosted their target price on Intuitive Surgical from $375.00 to $460.00 and gave the stock an “equal weight” rating in a research report on Monday, July 15th. Leerink Partners lifted their price target on Intuitive Surgical from $489.00 to $502.00 in a research note on Thursday. Finally, Raymond James increased their price objective on shares of Intuitive Surgical from $500.00 to $540.00 and gave the company an “outperform” rating in a research note on Monday, October 14th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and fourteen have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $513.74.

Intuitive Surgical Trading Up 10.0 %

Shares of ISRG stock opened at $521.15 on Friday. The stock has a 50 day simple moving average of $483.85 and a 200-day simple moving average of $438.17. The company has a market cap of $184.85 billion, a price-to-earnings ratio of 94.07, a price-to-earnings-growth ratio of 5.40 and a beta of 1.39. Intuitive Surgical has a 12-month low of $254.85 and a 12-month high of $523.34.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings data on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.54 by $0.24. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The firm had revenue of $2.01 billion during the quarter, compared to analysts’ expectations of $1.97 billion. During the same quarter in the prior year, the business posted $1.18 earnings per share. Intuitive Surgical’s revenue was up 14.5% compared to the same quarter last year. On average, equities analysts forecast that Intuitive Surgical will post 5.22 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, EVP Robert Desantis sold 1,413 shares of Intuitive Surgical stock in a transaction dated Friday, July 26th. The stock was sold at an average price of $438.60, for a total value of $619,741.80. Following the transaction, the executive vice president now directly owns 5,506 shares of the company’s stock, valued at $2,414,931.60. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. In other news, EVP Robert Desantis sold 1,413 shares of the firm’s stock in a transaction on Friday, July 26th. The shares were sold at an average price of $438.60, for a total value of $619,741.80. Following the transaction, the executive vice president now owns 5,506 shares of the company’s stock, valued at approximately $2,414,931.60. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, General Counsel Gary Loeb sold 300 shares of the business’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $475.00, for a total value of $142,500.00. Following the transaction, the general counsel now owns 1,595 shares in the company, valued at approximately $757,625. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 53,120 shares of company stock valued at $25,528,753. 0.90% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Intuitive Surgical

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. NBC Securities Inc. grew its position in shares of Intuitive Surgical by 34.4% during the first quarter. NBC Securities Inc. now owns 121 shares of the medical equipment provider’s stock worth $48,000 after buying an additional 31 shares in the last quarter. Massmutual Trust Co. FSB ADV increased its position in shares of Intuitive Surgical by 7.8% in the 1st quarter. Massmutual Trust Co. FSB ADV now owns 930 shares of the medical equipment provider’s stock worth $371,000 after purchasing an additional 67 shares during the last quarter. Signal Advisors Wealth LLC acquired a new stake in shares of Intuitive Surgical in the 1st quarter valued at about $203,000. &PARTNERS bought a new position in shares of Intuitive Surgical during the first quarter worth about $293,000. Finally, International Assets Investment Management LLC lifted its position in shares of Intuitive Surgical by 9.7% during the first quarter. International Assets Investment Management LLC now owns 2,234 shares of the medical equipment provider’s stock worth $882,000 after purchasing an additional 198 shares during the last quarter. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.